利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.032 秒)

    Novel hemopoietic receptor protein, NR10
    1.
    发明申请
    Novel hemopoietic receptor protein, NR10 有权

    公开(公告)号：US20100016552A1

    公开(公告)日：2010-01-21

    申请号：US11980117

    申请日：2007-10-30

    申请人： Masatsugu Maeda ,  Noriko Yaguchi

    发明人： Masatsugu Maeda ,  Noriko Yaguchi

    IPC分类号： C07K14/435

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K14/715 ,  C07K2319/00

    摘要： The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.

    Novel hemopoietin receptor protein, NR10
    5.
    发明申请
    Novel hemopoietin receptor protein, NR10 有权
    新型造血素受体蛋白NR10

    公开(公告)号：US20100240145A1

    公开(公告)日：2010-09-23

    申请号：US11980135

    申请日：2007-10-30

    申请人： Masatsugu Maeda ,  Noriko Yaguchi

    发明人： Masatsugu Maeda ,  Noriko Yaguchi

    IPC分类号： G01N33/566 ,  C07K16/18

    CPC分类号： C07K14/705 ,  A61K38/00 ,  C07K14/715 ,  C07K2319/00

    摘要： The inventors succeeded in isolating a novel hemopoietin receptor gene (NR10) using a sequence predicted from the extracted motif conserved in the amino acid sequences of known hemopoietin receptors. It was expected that two forms of NR10 exists, a transmembrane type and soluble form. Expression of the former type was detected in tissues containing hematopoietic cells. Thus, NR10 is a novel hemopoietin receptor molecule implicated in the regulation of the immune system and hematopoiesis in vivo. These novel receptors are useful in screening for novel hematopoietic factors capable of functionally binding to the receptor, or developing medicines to treat diseases related with the immune system or hematopoietic system.

    摘要翻译： 本发明人使用从已知的血细胞生成素受体的氨基酸序列中保存的提取的基序预测的序列成功地分离新的造血素受体基因（NR10）。 预期存在两种形式的NR10，跨膜型和可溶形式。 在含有造血细胞的组织中检测到前者的表达。 因此，NR10是一种涉及免疫系统调节和体内造血功能的新型促生长素受体分子。 这些新型受体可用于筛选能够与受体功能性结合的新型造血因子，或开发用于治疗与免疫系统或造血系统相关的疾病的药物。

    SGRF GENE-MODIFIED MOUSE
    6.
    发明申请
    SGRF GENE-MODIFIED MOUSE 有权
    SGRF基因修饰鼠

    公开(公告)号：US20090288177A1

    公开(公告)日：2009-11-19

    申请号：US12499694

    申请日：2009-07-08

    申请人： Kiyoshi Habu ,  Yuichi Hirata

    发明人： Kiyoshi Habu ,  Yuichi Hirata

    IPC分类号： A01K67/027

    CPC分类号： A01K67/0276 ,  A01K67/0271 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0325 ,  A01K2267/0368 ,  C12N15/8509 ,  C12N2800/30

    摘要： A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells in which one SGRF gene alleles was inactivated. By crossing these mice with each other, the present inventors succeeded in producing mice in which both SGRF gene alleles were inactivated. These genetically modified animals can be used to predict the side effects of drugs such as SGRF antagonists.

    摘要翻译： 通过用适当的药物标记基因取代SGRF基因中的外显子区域构建靶向载体。 将该载体转染入小鼠ES细胞系以获得嵌合小鼠，然后将其与C57BL / 6J小鼠杂交，以获得包含其中一个SGRF基因等位基因被灭活的细胞的小鼠。 通过使这些小鼠相互交叉，本发明人成功地生产了两种SGRF基因等位基因都被灭活的小鼠。 这些转基因动物可用于预测药物如SGRF拮抗剂的副作用。

    Transcriptional regulatory factor
    7.
    发明申请
    Transcriptional regulatory factor 审中-公开

    公开(公告)号：US20070249814A1

    公开(公告)日：2007-10-25

    申请号：US11728212

    申请日：2007-03-23

    申请人： Michael Jones

    发明人： Michael Jones

    IPC分类号： C07K16/18

    CPC分类号： C07K14/4702

    摘要： BLAST search was done on the EST database by using various nucleotide sequences encoding known bromodomain motifs to discover several ESTs likely encoding bromodomain genes. Next, testicular cDNAs were PCR cloned by using primers designed based on the sequence of EST (W17142), which is one of the ESTs discovered above. By using the thus obtained PCR product as a probe, the testicular library was screened. The obtained cDNA clone was used as a probe to re-screen the testicular cDNA library, thereby successfully isolating a full-length cDNA corresponding to EST (W17142). The protein encoded by the thus isolated cDNA had, in addition to the bromodomain, several regions and domains conserved in transcription regulatory factors. Moreover, the protein interacted with proteins associated with the chromatin-mediated transcriptional regulatory mechanism and a transcription co-activator.

    Transcriptional regulator
    8.
    发明申请
    Transcriptional regulator 失效

    公开(公告)号：US20070148738A1

    公开(公告)日：2007-06-28

    申请号：US11709624

    申请日：2007-02-22

    申请人： Michael Jones

    发明人： Michael Jones

    IPC分类号： C07K14/705 ,  C12P21/06 ,  C07H21/04

    CPC分类号： C12P21/02 ,  C07K14/4702

    摘要： Genes each encoding a novel transcriptional regulator having a bromodomain have been successfully isolated from a human testis cDNA library using primers prepared based on an EST sequence found using the bromodomain sequence of the transcriptional regulator. These genes are structurally analogous to each other.

    YS68 gene involved in primitive hematopoiesis
    9.
    发明申请
    YS68 gene involved in primitive hematopoiesis 有权
    涉及原始造血的YS68基因

    公开(公告)号：US20070087379A1

    公开(公告)日：2007-04-19

    申请号：US11643069

    申请日：2006-12-20

    申请人： Tetsuya Taga ,  Naoki Kimura

    发明人： Tetsuya Taga ,  Naoki Kimura

    IPC分类号： C12Q1/68 ,  C07H21/04 ,  C12P21/06 ,  C07K14/705

    CPC分类号： C07K14/47 ,  A61K38/00

    摘要： A novel gene, dubbed “YS68”, involved in primitive hematopoiesis was successfully isolated from cDNA derived from mouse yolk sacs. In addition, a human gene corresponding to this gene was successfully isolated. Expression characteristics of these genes suggested their involvement in primitive hematopoiesis. The proteins of this invention and genes encoding the proteins may be utilized as tools for drug development against diseases, such as hematological disorders.

    摘要翻译： 从源自小鼠卵黄囊的cDNA中成功分离了一种称为“YS68”的新基因，涉及原始造血。 此外，成功分离了与该基因相对应的人类基因。 这些基因的表达特征表明它们参与原始造血。 本发明的蛋白质和编码蛋白质的基因可以用作针对疾病如血液学疾病的药物开发的工具。

    Gene screening method using nuclear receptor
    10.
    发明申请
    Gene screening method using nuclear receptor 审中-公开
    使用核受体的基因筛选方法

    公开(公告)号：US20050158705A1

    公开(公告)日：2005-07-21

    申请号：US11030699

    申请日：2005-01-05

    申请人： Shigeaki Kato ,  Ken-Ichi Takeyama ,  Sachiko Kitanaka

    发明人： Shigeaki Kato ,  Ken-Ichi Takeyama ,  Sachiko Kitanaka

    IPC分类号： C07K14/705 ,  C12N9/02 ,  C12N15/10 ,  C12N15/60 ,  C12N15/63 ,  C12P21/08 ,  C12Q1/68 ,  C12Q1/6897 ,  C12Q1/00

    CPC分类号： C12N9/0077 ,  C07K14/70567 ,  C07K2319/00 ,  C12N15/1034 ,  C12N15/1086 ,  C12N15/63 ,  C12Q1/6897

    摘要： A system in which a ligand is formed by the expression of a polypeptide that converts a ligand precursor into a ligand, and the ligand thus formed binds to a nuclear receptor to thereby induce the expression of a reporter gene located downstream of the target sequence is constructed. Searching a gene library using this system can isolate a gene encoding a polypeptide capable of converting a ligand precursor into a ligand. This system, which takes the advantage of the transcriptional regulatory function of a nuclear receptor, enables screening a ligand that binds to a nuclear receptor and to examine whether or not a test compound is a ligand that binds to the nuclear receptor, and also screening genes that encode polypeptides capable of converting an inactive form of a wide range of transcriptional regulatory factors into an active form.

    摘要翻译： 其中通过表达将配体前体转化成配体的多肽而形成配体的系统，并且由此形成的配体与核受体结合从而诱导位于靶序列下游的报告基因的表达构建 。 使用该系统搜索基因文库可以分离编码能够将配体前体转化成配体的多肽的基因。 该系统利用核受体的转录调节功能，能够筛选与核受体结合的配体，并检查测试化合物是否是与核受体结合的配体，以及筛选基因 其编码能够将广泛范围的转录调节因子的无效形式转化为活性形式的多肽。